KSQ Therapeutics Entered into a Worldwide License Agreement with Roche to Develop and Commercialize KSQ-4279 for Cancer
Shots:
- KSQ will receive an up front & will be eligible to receive an additional milestone along with royalty. Under the terms of the agreement, Roche gets a global license & will be fully responsible for the further development of KSQ-4279 in 2024 in cancer patients
- Additionally, the collaboration focuses on delivering personalized healthcare, advancing KSQ’s immunotherapy programs, and to continue leveraging the CRISPRomics platform to discover novel targets
- KSQ-4279, a potent, and selective small molecule inhibitor of USP1 is currently in a P-I dose-escalation and expansion trial for the treatment of solid tumors
Ref: Businesswire | Image: KSQ
Related News:- Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
